Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06039956 | De-escalating Axillary Surgery in Breast Cancer Patients in Nigeria | not yet recruiting | N/A | 100 | Nova Scotia Health AuthorityOTHER | 0 | Aug 22, 2024 | clinicaltrials |
| NCT06566729 | MRD in High-risk EBC | active not recruiting | — | 125 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566937 | The Effectiveness of E-health Intervention in Improving Mental Health Outcomes Among Breast Cancer Patients | recruiting | N/A | 114 | National University of MalaysiaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06197581 | Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer(RADIOCOM) | recruiting | N/A | 148 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06176534 | Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial | recruiting | Phase 2 | 240 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06561646 | To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer | not yet recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06551896 | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 13, 2024 | clinicaltrials |
| NCT06548178 | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | not yet recruiting | Phase 2 | 242 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06548919 | Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer | recruiting | — | 450 | SciClone PharmaceuticalsINDUSTRY | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06549920 | Danish Breast Cancer Group Internal Mammary Node Study(DBCG IMN) | active not recruiting | N/A | 7,630 | Danish Breast Cancer Cooperative GroupOTHER | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06547476 | Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed | not yet recruiting | Phase 2 | 40 | Guangdong Provincial People's HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT04679454 | Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer | recruiting | N/A | 79 | European Institute of OncologyOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06531447 | First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients | active not recruiting | Phase 2 | 200 | The National Center of Oncology, AzerbaijanOTHER_GOV | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT03900637 | PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate | active not recruiting | Phase 2 | 122 | Seoul National University HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06503380 | Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530082 | A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer | not yet recruiting | Phase 1 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT03577197 | Southeast Netherlands Advanced Metastatic Breast Cancer Registry(SONABRE) | recruiting | — | 7,000 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06508216 | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer(COMPASS-TNBC) | recruiting | Phase 1 / Phase 2 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06236269 | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan(ACROSS-TROP2) | recruiting | Phase 2 | 50 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06510465 | Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)(NeoURANIA) | not yet recruiting | Phase 2 | 143 | RenJi HospitalOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT04353557 | ctDNA Monitoring in Early Breast Cancer | recruiting | — | 200 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06499168 | Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer | not yet recruiting | — | 45 | Assiut UniversityOTHER | 0 | Jul 12, 2024 | clinicaltrials |
| NCT06497322 | Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment | not yet recruiting | N/A | 60 | University Hospital of CologneOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06489821 | STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer(STAR-B) | not yet recruiting | N/A | 36 | Juravinski Cancer CenterOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT05549024 | 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients | recruiting | Early Phase 1 | 90 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05635487 | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | recruiting | Phase 2 | 65 | Shengjing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06483386 | Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer | not yet recruiting | Phase 2 | 109 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT04531696 | UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research(UPTIDER) | recruiting | N/A | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06475066 | Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging(COMBO-I) | not yet recruiting | N/A | 320 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472583 | Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer(BREAST-BOOSTER) | recruiting | Phase 2 | 78 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06470633 | To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT05216900 | Breast Reconstruction and Neoadjuvant Radiotherapy(BRENAR) | recruiting | N/A | 20 | UMC UtrechtOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05720260 | Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | recruiting | Phase 2 | 42 | National Taiwan University HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02958774 | Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation | active not recruiting | N/A | 388 | University of Kansas Medical CenterOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06345534 | FAST-FORWARD vs HAI5 | recruiting | N/A | 740 | University Hospital, GhentOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT05460975 | Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study) | recruiting | — | 16,164 | Seoul National University HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06422949 | Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy | not yet recruiting | N/A | 120 | European Institute of OncologyOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT03815890 | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO(BELLINI) | recruiting | Phase 2 | 80 | The Netherlands Cancer InstituteOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05851053 | Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study(BLOC-II) | recruiting | — | 455 | University Medical Center GroningenOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06429995 | Standard Follow-up Program (SFP) for Breast Cancer Patients(SFPMAMMA) | enrolling by invitation | — | 10,000 | University Medical Center GroningenOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT05077449 | A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer | active not recruiting | Phase 3 | 300 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT05731453 | Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening | active not recruiting | N/A | 80 | Vestre Viken Hospital TrustOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06389006 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | recruiting | Phase 2 | 79 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT06426810 | Electrosurgical Bipolar Systems Versus Conventional Electrocautery After SLNBx | recruiting | N/A | 40 | SMG-SNU Boramae Medical CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 22, 2024source: clinicaltrials